Home Cart Sign in  
Chemical Structure| 1650550-25-6 Chemical Structure| 1650550-25-6

Structure of Enasidenib mesylate
CAS No.: 1650550-25-6

Chemical Structure| 1650550-25-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Enasidenib mesylate is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes.

Synonyms: AG-221 mesylate; Idhifa

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Enasidenib mesylate

CAS No. :1650550-25-6
Formula : C20H21F6N7O4S
M.W : 569.48
SMILES Code : O=S(O)(C)=O.FC(F)(C1=NC(C2=NC(NCC(C)(C)O)=NC(NC3=CC(C(F)(F)F)=NC=C3)=N2)=CC=C1)F
Synonyms :
AG-221 mesylate; Idhifa
MDL No. :N/A

Safety of Enasidenib mesylate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
SW1353 49.47 μM 72 hours SW1353 cells showed intermediate sensitivity to enasidenib EBioMedicine. 2024 Apr;102:105090.
L2975 73.53 μM 72 hours L2975 cells were partially resistant to enasidenib EBioMedicine. 2024 Apr;102:105090.
CDS23 >100 μM 72 hours CDS23 cells were fully resistant to enasidenib EBioMedicine. 2024 Apr;102:105090.
CDS11 63.53 μM 72 hours CDS11 cells were partially resistant to enasidenib EBioMedicine. 2024 Apr;102:105090.
CDS17 16.65-22.65 μM 72 hours Enasidenib significantly reduced the viability of CDS17 cells EBioMedicine. 2024 Apr;102:105090.
KG-1 cells 5 μmol/L Enasidenib inhibited proliferation and promoted apoptosis in AML wild-type cells. However, in IDH2 mutant AML cells, the inhibitory effect of Enasidenib on proliferation was not significant, nor did it significantly promote apoptosis. Hematol Oncol. 2024 Nov;42(6):e3316.
HL-60 cells 5 μmol/L Enasidenib inhibited proliferation and promoted apoptosis in AML wild-type cells. However, in IDH2 mutant AML cells, the inhibitory effect of Enasidenib on proliferation was not significant, nor did it significantly promote apoptosis. Hematol Oncol. 2024 Nov;42(6):e3316.
IDH2-WT TF-1 erythroleukemic cell line 10 μM 8 days Enasidenib enhanced erythroid differentiation of IDH2-WT TF-1 erythroleukemic cell line. J Clin Invest. 2020 Apr 1;130(4):1843-1849.
CD34+ cells from normal human bone marrow 10 μM 8 days Enasidenib enhanced erythroid differentiation of CD34+ cells from normal human bone marrow, as evidenced by increased proportion of CD71+GPA+ cells. J Clin Invest. 2020 Apr 1;130(4):1843-1849.
CD34+ hematopoietic stem and progenitor cells (HSPCs) 1–25 μM 8 days Enasidenib enhanced erythroid differentiation of CD34+ HSPCs, as evidenced by increased proportion and number of CD71+GPA+ cells in a dose-dependent manner. J Clin Invest. 2020 Apr 1;130(4):1843-1849.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice T-CDS17#1 xenograft model Oral 35 mg/kg Twice a day for 21 days Enasidenib completely inhibited tumor growth and caused tumor regression EBioMedicine. 2024 Apr;102:105090.
Mice Idh2R140QFlt3ITD mutant AML model Oral 40mg/kg to 100mg/kg Twice daily for 4 to 6 weeks To evaluate the therapeutic effect of Enasidenib in vivo on Idh2R140QFlt3ITD mutant AML, showing reduction in serum 2HG levels, decreased proportion of cKit+ cells in peripheral blood, and partial restoration of bone marrow differentiation Cancer Discov. 2017 May;7(5):494-505
Mice IDH2 R140Q patient-derived xenografts Oral various doses Continuous treatment for 10-20 days AG-221 treatment resulted in upregulation of mature myeloid markers CD11b, CD14, CD15, and CD24, and a decrease in progenitor marker CD117, and differentiated cells retained the IDH2 R140Q mutation. In long-term survivors, blasts still persisted in the bone marrow with a significant mutant IDH2 allele burden. Cancer Discov. 2017 May;7(5):459-461

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.76mL

0.35mL

0.18mL

8.78mL

1.76mL

0.88mL

17.56mL

3.51mL

1.76mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories